Monday, May 15, 2023 Daily Archives

Fujifilm FY22: CDMO biz robust but COVID demand runs its course

Fujifilm has cited strong demand for process development and manufacturing work at its Denmark site as a key driver in its fiscal year 2022 results. For the full year ending 31 March 2023, Fujifilm Corporation reported sales in its healthcare division of ¥918 billion ($6.7 billion), up 14.5% on the year prior. Within the segment, the firm’s bio contract development and manufacturing organization (CDMO) businesses grew 29.2% year-on-year, pulling in ¥194 billion ($1.43 billion). “Revenue rose due mainly to strong…

Cali clinical plant to make ‘ImmPACT’ on CAR-Ts

ImmPACT Bio has opened a facility in LA to support IMPT-314, a CD19/CD20 bispecific CAR-T candidate for B-cell mediated malignancies and autoimmune diseases. The 21,500 square-foot facility in West Hills, Los Angeles includes two manufacturing suites dedicated to autologous cell therapy drug manufacturing, a QC lab, and space for future cleanroom expansion. The $15 million investment will support lead candidate IMPT-314 by accelerating clinical supply as the firm evolves its process and integrates automation. The chimeric antigen receptor (CAR) T-cell…

WHO-backed mRNA tech transfer platform looks beyond COVID, says MPP

Medicines Patent Pool (MPP) says its collaboration with the WHO helps to empower lower- and middle-income countries (LMIC) to manufacture vaccines and therapies locally. In 2021 the mRNA technology platform was founded by the World Health Organization (WHO) and Medicines Patent Pool (MPP) – a global health advocacy group funded by the multi-government initiative Unitaid. The collaboration, announced in response to the inequality in access to healthcare highlighted by the COVID-19 pandemic, aims to increase health security in LMICs, helping…

Recipharm biologics biz signs mRNA deal with MIT

ReciBioPharm (previously Arranta Bio) has partnered with MIT to develop a continuous manufacturing technology for mRNA therapeutics. The three-year deal is part of the US Food and Drugs Administration’s (FDA’s) initiative to create a fully integrated, continuous production line for messenger RNA (mRNA) vaccines, which will support future pandemic threats. The project aims to advance mRNA therapeutics to patients globally, not just for rapid response against future pandemic threat. The deal will also research mRNA therapeutics to treat rare diseases,…